Search Results - "BLEIN Stanislas" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis

Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis

by Rewerska, Barbara, Sher, Lawrence D., Alpizar, Sady, Pauser, Sylvia, Pulka, Grazyna, Mozaffarian, Neelufar, Salhi, Yacine, Martinet, Camille, Jabert, Wafaa, Gudi, Girish, CA, Vinu, GN, Sunitha, Macoin, Julie, Anstett, Victor, Turrini, Riccardo, Doucey, Marie-Agnès, Blein, Stanislas, Konto, Cyril, Machkova, Martina
Published in The journal of allergy and clinical immunology. Global (01.02.2024)

Get full text

Journal Article

A single mutation increases heavy-chain heterodimer assembly of bispecific antibodies by inducing structural disorder in one homodimer species

A single mutation increases heavy-chain heterodimer assembly of bispecific antibodies by inducing structural disorder in one homodimer species

by Stutz, Cian, Blein, Stanislas
Published in The Journal of biological chemistry (10.07.2020)

Get full text

Journal Article

Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies

Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies

by Skegro, Darko, Stutz, Cian, Ollier, Romain, Svensson, Emelie, Wassmann, Paul, Bourquin, Florence, Monney, Thierry, Gn, Sunitha, Blein, Stanislas
Published in The Journal of biological chemistry (09.06.2017)

Get full text

Journal Article

Structural Analysis of the Complement Control Protein (CCP) Modules of GABAB Receptor 1a

Structural Analysis of the Complement Control Protein (CCP) Modules of GABAB Receptor 1a

by Blein, Stanislas, Ginham, Rachel, Uhrin, Dušan, Smith, Brian O., Soares, Dinesh C., Veltel, Stefvan, McIlhinney, R. A. Jeffrey, White, Julia H., Barlow, Paul N.
Published in The Journal of biological chemistry (01.11.2004)

Get full text

Journal Article

$Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma$

Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma

by Pouleau, Blandine, Estoppey, Carole, Suere, Perrine, Nallet, Emilie, Laurendon, Amélie, Monney, Thierry, Pais Ferreira, Daniela, Drake, Adam, Carretero-Iglesia, Laura, Macoin, Julie, Berret, Jérémy, Pihlgren, Maria, Doucey, Marie-Agnès, Gudi, Girish S., Menon, Vinu, Udupa, Venkatesha, Maiti, Abhishek, Borthakur, Gautam, Srivastava, Ankita, Blein, Stanislas, Mbow, M. Lamine, Matthes, Thomas, Kaya, Zeynep, Edwards, Claire M., Edwards, James R., Menoret, Emmanuelle, Kervoëlen, Charlotte, Pellat-Deceunynck, Catherine, Moreau, Philippe, Zhukovsky, Eugene, Perro, Mario, Chimen, Myriam
Published in Blood (20.07.2023)

Get full text

Journal Article

$ISB 1342: A first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma$

ISB 1342: A first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma

by Doucey, Marie-Agnès, Pouleau, Blandine, Estoppey, Carole, Stutz, Cian, Croset, Amelie, Laurendon, Amélie, Monney, Thierry, Pluess, Mégane, Ries-Fecourt, Christelle, Macoin, Julie, Turrini, Riccardo, Suere, Perrine, Mbow, M.Lamine, Nallet, Emilie, Drake, Adam, Perro, Mario, Blein, Stanislas
Published in Journal of clinical oncology (20.05.2021)

Get full text

Journal Article

ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma By Targeting Two Antigens

ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma By Targeting Two Antigens

by Pihlgren, Maria, Hall, Olivia, Carretero, Laura, Estoppey, Carole, Drake, Adam, Pais, Daniela, Loyau, Jeremy, Berret, Jeremy, Gruber, Isabelle, Suere, Perrine, Schnorhk, Vincent, Nallet, Emilie, Pouleau, Blandine, Chimen, Myriam, Macoin, Julie, Stainnack, Elodie, Monney, Thierry, Delachat, Aurore, Dreyfus, Cyrille, Matthes, Thomas, Konto, Cyril, Dyson, Michael, Blein, Stanislas, Mbow, Lamine, Wood, Rebecca, Srivastava, Ankita, Zhukovsky, Eugene, Perro, Mario
Published in Blood (15.11.2022)

Get full text

Journal Article

$Pre-clinical characterization of ISB 1342, a CD38xCD3 T-cell engager for relapsed/refractory multiple myeloma$

Pre-clinical characterization of ISB 1342, a CD38xCD3 T-cell engager for relapsed/refractory multiple myeloma

by Pouleau, Blandine, Estoppey, Carole, Suere, Perrine, Nallet, Emilie, Laurendon, Amélie, Monney, Thierry, Pais Ferreira, Daniela, Drake, Adam, Carretero-Iglesia, Laura, Macoin, Julie, Berret, Jeremy, Pihlgren, Maria, Doucey, Marie-Agnes, Gudi, Girish S, Menon, Vinu, Udupa, Venkatesha, Maiti, Abhishek, Borthakur, Gautam, Srivastava, Ankita, Blein, Stanislas, Mbow, Lamine, Matthes, Thomas, Kaya, Zeynep, Edwards, Claire M, Edwards, James R, Menoret, Emmanuelle, Kervoelen, Charlotte, Pellat-Deceunynck, Catherine, Moreau, Philippe, Zhukovsky, Eugene Alexander, Perro, Mario, Chimen, Myriam
Published in Blood (16.05.2023)

Get full text

Journal Article

Hetero-dimeric Immunoglobulins

Hetero-dimeric Immunoglobulins

by BLEIN STANISLAS, WASSMANN PAUL, SKEGRO DARKO
Year of Publication 14.05.2020

Get full text

Patent

$ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma$

ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma

by Stefano, Sammicheli, Grandclement, Camille, Dehilly, Elie, Panagopoulou, Maria, Martini, Evangelia, Castillo, Rosa, Suere, Perrine, Pouleau, Blandine, Estoppey, Carole, Frei, Julia, Loyau, Jeremy, Monney, Thierry, Wood, Rebecca, Croset, Amelie, Rubod, Alain, Gudi, Girish, Udupa, Venkatesha, Gn, Sunitha, Menon, Vinu, Rasmussen, Daniel, Olsen, Jeppe Koch, Giovannini, Roberto, Chakrapani, Aravind, Blein, Stanislas, Doucey, Marie-Agnes, Drake, Adam, Riva, Alessandro, Konto, Cyril, Perro, Mario, Mbow, Lamine
Published in Blood (23.11.2021)

Get full text

Journal Article

EGFR 양성 암의 치료를 위한 T 세포 재지시성 이중특이적 항체

EGFR 양성 암의 치료를 위한 T 세포 재지시성 이중특이적 항체

by BLEIN STANISLAS, LISSILAA RAMI, STUTZ CIAN
Year of Publication 08.01.2020

Get full text

Patent

Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development

Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development

by Ollier, Romain, Wassmann, Paul, Monney, Thierry, Ries Fecourt, Christelle, Gn, Sunitha, C A, Vinu, Ayoub, Daniel, Stutz, Cian, Gudi, Girish S, Blein, Stanislas
Published in mAbs (17.11.2019)

Get full text

Journal Article

CD47-CD38 이중특이성 항체

CD47-CD38 이중특이성 항체

by DOUCEY MARIE ANGES, GRANDCELMENT CAMILLE, POULEAU BLANDINE, BOUCHEZ LAURE, LOYAU JEREMY, BLEIN STANISLAS, MONNEY THIERRY, SAMMICHELI STEFANO, ESTOPPEY CAROLE, DHEILLY ELIE, STUTZ CIAN
Year of Publication 19.06.2023

Get full text

Patent

OX40 Antibodies that bind to OX40 and their uses

OX40 Antibodies that bind to OX40 and their uses

by ATTINGER ANTOINE, BLEIN STANISLAS, HOU SAMUEL, BACK JONATHAN ALBERT, LISSILAA RAMI
Year of Publication 11.06.2020

Get full text

Patent

신규 TNFR 효능제 및 이의 용도

신규 TNFR 효능제 및 이의 용도

by BLEIN STANISLAS, MACOIN JULIE, ROUSSEAU FRANCOIS, BACK JONATHAN, LISSILAA RAMI, STUTZ CIAN
Year of Publication 16.08.2019

Get full text

Patent

ANTI-TRKA ANTIBODIES WITH ENHANCED INHIBITORY PROPERTIES AND DERIVATIVES THEREOF

ANTI-TRKA ANTIBODIES WITH ENHANCED INHIBITORY PROPERTIES AND DERIVATIVES THEREOF

by BLEIN STANISLAS, OLLIER ROMAIN, SKEGRO DARKO
Year of Publication 05.03.2015

Get full text

Patent

ANTI-ALPHA2 INTEGRIN ANTIBODIES AND THEIR USES

ANTI-ALPHA2 INTEGRIN ANTIBODIES AND THEIR USES

by BLEIN STANISLAS, HOW SAMUEL, SKEGRO DARKO
Year of Publication 27.01.2015

Get full text

Patent

Abstract C164: Preclinical pharmacological characterization of GBR 401, a new monoclonal antibody directed against human CD19

Abstract C164: Preclinical pharmacological characterization of GBR 401, a new monoclonal antibody directed against human CD19

by Hou, Samuel, Blein, Stanislas, Skegro, Darko, Macoin, Julie, Lissilaa, Rami, Back, Jonathan
Published in Molecular cancer therapeutics (12.11.2011)

Get full text

Journal Article

PRODUCTION OF T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS

PRODUCTION OF T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS

by BLEIN STANISLAS, HOU SAMUEL, OLLIER ROMAIN, SKEGRO DARKO
Year of Publication 29.07.2016

Get full text

Patent

HETERO-DIMERIC IMMUNOGLOBULINS

HETERO-DIMERIC IMMUNOGLOBULINS

by BLEIN STANISLAS, WASSMANN PAUL, SKEGRO DARKO
Year of Publication 23.12.2013

Get full text

Patent

1
2
3
4
5
6
7
8
9
10
11
Next
[15]